175 related articles for article (PubMed ID: 30863782)
1. Serum Leucine-Rich
Shimizu M; Inoue N; Mizuta M; Nakagishi Y; Yachie A
J Immunol Res; 2019; 2019():3140204. PubMed ID: 30863782
[TBL] [Abstract][Full Text] [Related]
2. Leucine-rich α2-glycoprotein as the acute-phase reactant to detect systemic juvenile idiopathic arthritis disease activity during anti-interleukin-6 blockade therapy: A case series.
Shimizu M; Nakagishi Y; Inoue N; Mizuta M; Yachie A
Mod Rheumatol; 2017 Sep; 27(5):833-837. PubMed ID: 28094589
[TBL] [Abstract][Full Text] [Related]
3. Soluble CD163, a unique biomarker to evaluate the disease activity, exhibits macrophage activation in systemic juvenile idiopathic arthritis.
Sakumura N; Shimizu M; Mizuta M; Inoue N; Nakagishi Y; Yachie A
Cytokine; 2018 Oct; 110():459-465. PubMed ID: 29801971
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of interleukin-18 for the diagnosis and prediction of disease course in systemic juvenile idiopathic arthritis.
Mizuta M; Shimizu M; Inoue N; Ikawa Y; Nakagishi Y; Yasuoka R; Iwata N; Yachie A
Rheumatology (Oxford); 2021 May; 60(5):2421-2426. PubMed ID: 33200207
[TBL] [Abstract][Full Text] [Related]
5. Serum IL-18 as a potential specific marker for differentiating systemic juvenile idiopathic arthritis from incomplete Kawasaki disease.
Takahara T; Shimizu M; Nakagishi Y; Kinjo N; Yachie A
Rheumatol Int; 2015 Jan; 35(1):81-4. PubMed ID: 24917023
[TBL] [Abstract][Full Text] [Related]
6. Comparison of serum biomarkers for the diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis during tocilizumab therapy.
Irabu H; Shimizu M; Kaneko S; Inoue N; Mizuta M; Nakagishi Y; Yachie A
Pediatr Res; 2020 Dec; 88(6):934-939. PubMed ID: 32184444
[TBL] [Abstract][Full Text] [Related]
7. Serum ferritin levels as a useful diagnostic marker for the distinction of systemic juvenile idiopathic arthritis and Kawasaki disease.
Mizuta M; Shimizu M; Inoue N; Kasai K; Nakagishi Y; Takahara T; Hamahira K; Yachie A
Mod Rheumatol; 2016 Nov; 26(6):929-932. PubMed ID: 27433933
[TBL] [Abstract][Full Text] [Related]
8. Soluble ST2 as a marker of disease activity in systemic juvenile idiopathic arthritis.
Ishikawa S; Shimizu M; Ueno K; Sugimoto N; Yachie A
Cytokine; 2013 May; 62(2):272-7. PubMed ID: 23561929
[TBL] [Abstract][Full Text] [Related]
9. Comparison of serum cytokine profiles in macrophage activation syndrome complicating different background rheumatic diseases in children.
Mizuta M; Shimizu M; Irabu H; Usami M; Inoue N; Nakagishi Y; Wada T; Yachie A
Rheumatology (Oxford); 2021 Jan; 60(1):231-238. PubMed ID: 32681176
[TBL] [Abstract][Full Text] [Related]
10. Serum leucine-rich α2-glycoprotein is a useful biomarker for monitoring disease activity in patients with adult-onset Still's disease.
Ha YJ; Kang EJ; Lee SW; Park YB; Lee SK; Song JS; Choi ST
Scand J Rheumatol; 2015; 44(5):399-403. PubMed ID: 26079682
[TBL] [Abstract][Full Text] [Related]
11. Compensated inflammation in systemic juvenile idiopathic arthritis: role of alternatively activated macrophages.
Shimizu M; Yachie A
Cytokine; 2012 Oct; 60(1):226-32. PubMed ID: 22682876
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of serum CXCL9 levels as a biomarker for systemic juvenile idiopathic arthritis associated macrophage activation syndrome.
Mizuta M; Shimizu M; Inoue N; Nakagishi Y; Yachie A
Cytokine; 2019 Jul; 119():182-187. PubMed ID: 30952065
[TBL] [Abstract][Full Text] [Related]
13. Serum interleukin-18 level as a possible early diagnostic marker of systemic juvenile idiopathic arthritis.
Souma K; Fujimura J; Nishiyama A; Oyazato Y; Kaneko S; Shimizu M; Morisawa T
Int J Rheum Dis; 2023 Mar; 26(3):551-553. PubMed ID: 36527182
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-18 as a mediator of systemic juvenile idiopathic arthritis.
Jelusić M; Lukić IK; Tambić-Bukovac L; Dubravcić K; Malcić I; Rudan I; Batinić D
Clin Rheumatol; 2007 Aug; 26(8):1332-4. PubMed ID: 17597334
[TBL] [Abstract][Full Text] [Related]
15. Serum leucine-rich alpha-2 glycoprotein is a disease activity biomarker in ulcerative colitis.
Serada S; Fujimoto M; Terabe F; Iijima H; Shinzaki S; Matsuzaki S; Ohkawara T; Nezu R; Nakajima S; Kobayashi T; Plevy SE; Takehara T; Naka T
Inflamm Bowel Dis; 2012 Nov; 18(11):2169-79. PubMed ID: 22374925
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-33 as a marker of disease activity in rheumatoid factor positive polyarticular juvenile idiopathic arthritis.
Ishikawa S; Shimizu M; Inoue N; Mizuta M; Nakagishi Y; Yachie A
Mod Rheumatol; 2017 Jul; 27(4):609-613. PubMed ID: 27785924
[TBL] [Abstract][Full Text] [Related]
17. Characteristic elevation of soluble TNF receptor II : I ratio in macrophage activation syndrome with systemic juvenile idiopathic arthritis.
Shimizu M; Inoue N; Mizuta M; Nakagishi Y; Yachie A
Clin Exp Immunol; 2018 Mar; 191(3):349-355. PubMed ID: 28815559
[TBL] [Abstract][Full Text] [Related]
18. Proinflammatory cytokines in monitoring the course of disease and effectiveness of treatment with etanercept (ETN) of children with oligo- and polyarticular juvenile idiopathic arthritis (JIA).
Kaminiarczyk-Pyzalka D; Adamczak K; Mikos H; Klimecka I; Moczko J; Niedziela M
Clin Lab; 2014; 60(9):1481-90. PubMed ID: 25291944
[TBL] [Abstract][Full Text] [Related]
19. The presence of high mobility group box-1 and soluble receptor for advanced glycation end-products in juvenile idiopathic arthritis and juvenile systemic lupus erythematosus.
Bobek D; Grčević D; Kovačić N; Lukić IK; Jelušić M
Pediatr Rheumatol Online J; 2014; 12():50. PubMed ID: 25516724
[TBL] [Abstract][Full Text] [Related]
20. [Cytokine levels in serum of patients with juvenile idiopathic arthritis depending on subtype and disease activity].
Pietrewicz E; Urban M; Górska A
Pol Merkur Lekarski; 2004 Sep; 17(99):232-4. PubMed ID: 15628047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
